Volume 23, Issue 3 (Autumn 2026)                   bloodj 2026, 23(3): 251-265 | Back to browse issues page

Ethics code: IR.UMSHA.REC.1403.317

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dahaghin Z, Amiri F. Clinical Management of Graft-versus-Host Disease Through the Immunomodulatory Properties of Mesenchymal Stem Cells: From Prophylaxis to Salvage therapy. , bloodj. 2026; 23 (3) :251-265
URL: http://bloodjournal.ir/article-1-1637-en.html
Abstract:   (21 Views)
A B S T R A C T
Background and Objectives
Graft-versus-host disease (GVHD) remains one of the most important challenges and life-threatening complications following allogeneic hematopoietic stem cell transplantation (HSCT). Given the limitations and potentially severe adverse effects of conventional immunosuppressive therapies and corticosteroids, the application of mesenchymal stem cells (MSCs) has attracted considerable attention as a novel cell-based therapeutic strategy. This review aims to elucidate the mechanisms of action, evaluate the available clinical evidence, and define the paradigm of MSCs in various GVHD management strategies, encompassing prophylaxy and primary treatments, as well as salvage therapy for steroid-refractory cases.
Materials and Methods
This study was designed as a narrative review. A literature search was conducted in major scientific databases, including PubMed, Scopus, and Web of Science. The main search terms included “Mesenchymal Stem Cells,” “Graft-Versus-Host Disease,” “Immunomodulation,” and “Cell Therapy.” Articles published between 2000 and 2026 were retrieved. Basic studies and clinical trials investigating the role of MSCs in the prevention and treatment of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD) were included. Review articles, editorials, letters to the editor, conference abstracts, duplicate publications, and studies not directly related to MSC-based interventions in GVHD were excluded. Retrieved records were first screened by title and abstract, followed by full-text assessment for relevance. Studies were selected based on their relevance to the therapeutic mechanisms, clinical efficacy, the limitations and transfer capacity of MSCs in the context of GVHD were investigated.
Results
Accumulating clinical and preclinical evidence indicates that mesenchymal stem/stromal cells (MSCs) exert their therapeutic effects through diverse mechanisms, including the secretion of paracrine factors and direct cell–cell interactions. These mechanisms   contribute to the  attenuation of cytokine storm and promote the induction of regulatory T cells (Tregs). The clinical applications of MSCs can be broadly categorized into two main areas: prophylactic administration (concomitant with transplantation) and therapeutic use, particularly as salvage therapy in steroid-refractory cases.
Conclusions 
By shifting the inflammatory response towards immune tolerance, MSCs represent a highly powerful tool in controlling GVHD. Nevertheless, the standardization of optimal dosing and cellular sources, along with further investigation  of cell-free derivatives, such as exosomes, is essential for optimizing this treatment strategy in the future.
 
Full-Text [PDF 1090 kb]   (2 Downloads)    
Type of Study: Review Article | Subject: Imunohematology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Journal of Iranian Blood Transfusion

Designed & Developed by: Yektaweb